Brimonidine for erythema caused by rosacea.

Brimonidine gel (Mirvaso-Galderma) became available in February of this year for the symptomatic treatment of facial erythema associated with rosacea in adults.1 Here, we review the evidence on brimonidine gel and consider its place in the management of erythema associated with rosacea.

《-》

[Erythema of rosacea: a new and effective treatment].

Until recently, our rosacea patients have had to suffer of their erythema with limited effective treatments. Mirvaso(®) (Brimonidine tartrate 0.5%, Brimonidine 3mg/g) is a new medication, indicated for the treatment of the erythema of rosacea. The phase III pivotal and long term studies showing the efficacy and tolerability of Mirvaso(®) are summarized.

Hougeir FG 《ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE》

Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.

Tong LX ，Moore AY 《-》

Brimonidine gel (Mirvaso) for rosacea.

《-》

Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.

Facial redness contributes to impaired psychosocial functioning in rosacea patients and the only approved treatment for erythema is topical brimonidine gel 0.33%. To evaluate patient-reported outcomes, as well as efficacy and safety, in subjects with self-perceived severe erythema treated with brimonidine gel 0.33% compared to vehicle. An 8-day multicenter, randomized study comparing once-daily brimonidine gel 0.33% with vehicle gel using a facial redness questionnaire, subject satisfaction questionnaire and a patient diary of facial redness control to assess patient-reported outcomes. Of the 92 included subjects with self-perceived severe erythema, very few were satisfied with their appearance at baseline (4.2% brimonidine group, 0 vehicle group). On Day 8, significantly more brimonidine group subjects were satisfied with their facial appearance compared to vehicle group (36.9% vs. 21.5%; P < 0.05), with the overall treatment effect (69.6% vs. 40.4%; P < 0.01), and with the improvement in their facial redness (67.4% vs. 33.3%; P < 0.001). More brimonidine group subjects were able to control their facial redness daily (e.g. 83.0% vs. 38.9% on Day 1). On Day 8, significantly more brimonidine group subjects than vehicle group had at least a one-grade improvement from baseline in the Clinician Erythema Assessment score (71.7% vs. 35.7%; P = 0.0011) and Patient Self-Assessment score (76.1% vs. 47.6%; P = 0.004). More subjects in the brimonidine group (29.2%) reported treatment-related adverse events than in the vehicle group (15.9%) but most were mild and transient. Once-daily brimonidine gel 0.33% allowed patients to rapidly control their facial redness and significantly improved patient-reported outcomes in the treatment of persistent facial erythema of rosacea.

Layton AM ，Schaller M ，Homey B ，Hofmann MA ，Bewley AP ，Lehmann P ，Nohlgård C ，Sarwer DB ，Kerrouche N ，Ma YM ... -  《-》